ES2199058B1 - Reactivo de latex para la deteccion de anticuerpos frente a micoplasmaneumoniae. - Google Patents

Reactivo de latex para la deteccion de anticuerpos frente a micoplasmaneumoniae.

Info

Publication number
ES2199058B1
ES2199058B1 ES200201298A ES200201298A ES2199058B1 ES 2199058 B1 ES2199058 B1 ES 2199058B1 ES 200201298 A ES200201298 A ES 200201298A ES 200201298 A ES200201298 A ES 200201298A ES 2199058 B1 ES2199058 B1 ES 2199058B1
Authority
ES
Spain
Prior art keywords
sensitized
mycoplasma pneumoniae
particles
antibodies against
detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200201298A
Other languages
English (en)
Other versions
ES2199058A1 (es
Inventor
Jose Antonio Molina Bolivar
Jose Manuel Peula Garcia
Joaquin Mendoza Montero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad de Malaga
Original Assignee
Universidad de Malaga
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad de Malaga filed Critical Universidad de Malaga
Priority to ES200201298A priority Critical patent/ES2199058B1/es
Publication of ES2199058A1 publication Critical patent/ES2199058A1/es
Application granted granted Critical
Publication of ES2199058B1 publication Critical patent/ES2199058B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56933—Mycoplasma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Reactivo de látex para la detección de anticuerpos frente a Mycoplasma pneumoniae. Se describe un procedimiento (test de inmunodiagnóstico) para detectar y cuantificar anticuerpos específicos de Mycoplasma pneumoniae presentes en muestras serológicas, mediante la aglutinación-sedimentación de partículas de látex sensibilizadas con un antígeno lipídico de Mycoplasma pneumoniae. Asimismo se describe el método de obtención de las partículas de látex sensibilizadas y el tampón de reacción donde se desarrolla la inmunorreacción. El desarrollo del inmunodiagnóstico tiene lugar en los pocillos de una placa de microtitulación mezclando las partículas sensibilizadas con muestras de sueros humanos en un tampón de reacción específico. La presencia en el suero de anticuerpos frente Mycoplasma pneumoniae se detecta mediante la aglutinación de las partículas de látex sensibilizadas. La ausencia de anticuerpos específicos se detecta mediante la sedimentación de éstas partículas. Este test de inmunodiagnóstico es económico, técnicamente simple, tiene una elevada estabilidad temporal y presenta unos niveles de sensibilidad y especificidad adecuados.
ES200201298A 2002-06-06 2002-06-06 Reactivo de latex para la deteccion de anticuerpos frente a micoplasmaneumoniae. Expired - Fee Related ES2199058B1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES200201298A ES2199058B1 (es) 2002-06-06 2002-06-06 Reactivo de latex para la deteccion de anticuerpos frente a micoplasmaneumoniae.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200201298A ES2199058B1 (es) 2002-06-06 2002-06-06 Reactivo de latex para la deteccion de anticuerpos frente a micoplasmaneumoniae.

Publications (2)

Publication Number Publication Date
ES2199058A1 ES2199058A1 (es) 2004-02-01
ES2199058B1 true ES2199058B1 (es) 2005-02-16

Family

ID=31198096

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200201298A Expired - Fee Related ES2199058B1 (es) 2002-06-06 2002-06-06 Reactivo de latex para la deteccion de anticuerpos frente a micoplasmaneumoniae.

Country Status (1)

Country Link
ES (1) ES2199058B1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS566161A (en) * 1979-06-28 1981-01-22 Seikagaku Kogyo Co Ltd Erythropoietin sensitized latex
JPS60209179A (ja) * 1984-04-02 1985-10-21 Tetsuo Tomiyama 肺炎マイコプラズマ脂質抗原レシチン複合物感作ラテツクス試薬及びそれを用いた肺炎マイコプラズマ抗体の検出方法
WO1992014154A1 (en) * 1991-02-12 1992-08-20 Dynagen, Inc. Agglutination test for mycobacterial antigens in biological samples

Also Published As

Publication number Publication date
ES2199058A1 (es) 2004-02-01

Similar Documents

Publication Publication Date Title
Nicol et al. Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech)
Schnurra et al. Comparison of the diagnostic sensitivity of SARS-CoV-2 nucleoprotein and glycoprotein-based antibody tests
Sidiq et al. Benefits and limitations of serological assays in COVID-19 infection
Dobaño et al. Highly sensitive and specific multiplex antibody assays to quantify immunoglobulins M, A, and G against SARS-CoV-2 antigens
Liu et al. Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates
ITCZ20020002A1 (it) Dispositivo e metodo per il rilevamento simultaneo di differenti anticorpi e antigeni in campioni clinici, alimentari ed ambientali
EA200971114A1 (ru) Определение антигенов, расположенных на эритроцитах, и антиэритроцитарных антител
DK1322956T3 (da) Fremgangsmåde til diagnose af immunologisk födevarefölsomhed
ATE475885T1 (de) Verfahren zum testen eines antigens und reagens dafür
RU2013118307A (ru) Новый способ диагностики белезни лайма с использованием теста клеточного иммунного ответа
Garnett et al. Clinical validation and performance evaluation of the automated vitros total anti–SARS-CoV-2 antibodies assay for screening of serostatus in COVID-19
ATE489632T1 (de) Antigennachweis
Emmerich et al. Longitudinal detection of SARS‐CoV‐2‐specific antibody responses with different serological methods
Valdivia et al. Caveats in interpreting SARS‐CoV‐2 IgM+/IgG− antibody profile in asymptomatic health care workers
Khan et al. Enzyme-linked immunosorbent assay versus chemiluminescent immunoassay: A general overview
Ruano‐Gallego et al. A multiplex antigen microarray for simultaneous IgG and IgM detection against SARS‐CoV‐2 reveals higher seroprevalence than reported
Wechselberger et al. Performance evaluation of serological assays to determine the immunoglobulin status in SARS-CoV-2 infected patients
SE0103688D0 (sv) Method and device for immunoassay
Dhanalakshmi et al. Seroprevalence of Entamoeba histolytica from a tertiary care hospital, South India
Naguleswaran et al. Elaboration of a crude antigen ELISA for serodiagnosis of caprine neosporosis: validation of the test by detection of Neospora caninum-specific antibodies in goats from Sri Lanka
Knauer et al. Interim analysis of the clinical performance of five SARS-Cov-2 serology assays
Singh et al. A handy field-portable ELISA system for rapid onsite diagnosis of infectious diseases
Yang et al. Eu3+/Sm3+ dual‐label time‐resolved fluoroimmunoassay for measurement of hepatitis C virus antibodies
ES2199058B1 (es) Reactivo de latex para la deteccion de anticuerpos frente a micoplasmaneumoniae.
Ekström et al. Analytical and clinical evaluation of antibody tests for SARS-CoV-2 serosurveillance studies used in Finland in 2020

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20040201

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2199058B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20220629